{
    "id": "58946a22-16dc-4cdd-9898-8e1186c4bcbc",
    "code": {
        "code": "34391-3",
        "codeSystem": "2.16.840.1.113883.6.1",
        "displayName": "HUMAN PRESCRIPTION DRUG LABEL"
    },
    "name": "Nystop",
    "organization": "Bryant Ranch Prepack",
    "effectiveTime": "20250402",
    "ingredients": [
        {
            "name": "NYSTATIN",
            "code": "BDF1O1C72E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        }
    ],
    "indications": "usage nystatin topical powder indicated treatment cutaneous mucocutaneous mycotic infections caused candida albicans susceptible candida species. preparation indicated systemic, oral, intravaginal ophthalmic use.",
    "contraindications": "nystatin topical powder contraindicated patients history hypersensitivity components.",
    "warningsAndPrecautions": "general nystatin topical powder used treatment systemic, oral, intravaginal ophthalmic infections. irritation sensitization develops, treatment discontinued appropriate measures taken indicated. recommended koh smears, cultures, diagnostic methods used confirm diagnosis cutaneous mucocutaneous candidiasis rule infection caused pathogens. information patient patients using medication receive following information instructions: 1. patient instructed medication directed ( including replacement missed doses ) . medication disorder prescribed. 2. even symptomatic relief occurs within first days treatment, patient advised interrupt discontinue therapy prescribed course treatment completed. 3. symptoms irritation develop, patient advised notify physician promptly. laboratory tests lack therapeutic response, koh smears, cultures, diagnostic methods repeated. carcinogenesis, mutagenesis, impairment fertility long-term animal performed evaluate carcinogenic potential nystatin. performed determine mutagenicity nystatin effects male female fertility pregnancy: teratogenic effects category c. animal reproduction conducted nystatin topical preparation. also known whether preparations cause fetal harm used pregnant woman affect reproductive capacity. nystatin topical preparations prescribed pregnant woman potential benefit mother outweighs potential risk fetus. nursing mothers known whether nystatin excreted human milk. caution exercised nystatin prescribed nursing woman. pediatric safety effectiveness established pediatric population birth 16 years. ( ) .",
    "adverseReactions": "frequency events reported patients using nystatin topical preparations less 0.1% . common events reported include allergic reactions, burning, itching, rash, eczema, pain application. ( precautions: general . )",
    "indications_original": "INDICATIONS AND USAGE Nystatin Topical Powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. This preparation is not indicated for systemic, oral, intravaginal or ophthalmic use.",
    "contraindications_original": "CONTRAINDICATIONS Nystatin Topical Powder is contraindicated in patients with a history of hypersensitivity to any of its components.",
    "warningsAndPrecautions_original": "PRECAUTIONS General Nystatin Topical Powder should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens. INFORMATION FOR THE PATIENT Patients using this medication should receive the following information and instructions: 1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed. 2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed. 3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly. Laboratory Tests If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility Pregnancy: Teratogenic Effects Category C. Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus. Nursing Mothers It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman. Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION ).",
    "adverseReactions_original": "ADVERSE REACTIONS The frequency of adverse events reported in patients using nystatin topical preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General .)"
}